Clinical Trial Update: Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor [Phase 4]

View source ↗

Summary

This Phase 4 trial evaluated andexanet alfa as an antidote for acute intracranial hemorrhage in patients taking an oral Factor Xa inhibitor. The study has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intracranial Hemorrhage

Drugs mentioned

• AndexXa (andexanet alfa)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Acute Intracranial Hemorrhage | Phase 4 | Status: COMPLETED | Results posted: 2024-07-03